Skip to main
MGTX

MGTX Stock Forecast & Price Target

MGTX Analyst Ratings

Based on 7 analyst ratings
Strong Buy
Strong Buy 57%
Buy 43%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

MeiraGTx Holdings is a promising biotechnology company with a diverse pipeline and strong in-house manufacturing capabilities. The company's recent financing deal with Oberland Capital provides additional funds to support development and commercialization activities for its lead programs in xerostomia and retinal diseases. Risks to the outlook include delays in advancing pipeline candidates and potential dilution of equity. However, the company's focus on sustainable and ethical practices, as well as its collaborations with patient support groups, demonstrate its commitment to making a positive impact in the healthcare industry.

Bears say

MeiraGTx Holdings is a clinical-stage genetic medicines company operating in the United States, the United Kingdom, and the European Union. Despite its focus on developing targeted therapies for diseases with high unmet needs, the company has a history of ongoing net losses and faces risks such as clinical program execution, regulatory uncertainties, and competition. Its recent strategic partnership for its Parkinson's program may provide some financial relief, but the company's speculative nature and unpredictable future revenues and expenses warrant a negative outlook.

MGTX has been analyzed by 7 analysts, with a consensus rating of Strong Buy. 57% of analysts recommend a Strong Buy, 43% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of MeiraGTx Holdings plc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About MeiraGTx Holdings plc (MGTX) Forecast

Analysts have given MGTX a Strong Buy based on their latest research and market trends.

According to 7 analysts, MGTX has a Strong Buy consensus rating as of Jul 18, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $24.86, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $24.86, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

MeiraGTx Holdings plc (MGTX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.